The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Coding Corner Answer: December Coding Challenge

Coding Corner Answer: December Coding Challenge

December 1, 2012 • By Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Test Your Coding Skills for the Certified Rheumatology Coder Course and Exam…

You Might Also Like
  • Coding Corner Answer: July Coding Challenge
  • Coding Corner Answer: August Coding Challenge
  • Coding Corner Question: December
Explore This Issue
December 2012
Also By This Author
  • What Subliminal Cues Are Lurking in Your Waiting Room?
  1. D: High: The patient has one established problem worsening—severe rheumatoid arthritis—and one new problem with work up—adverse reaction to infusion. The amount of data reviewed or ordered was none. The patient’s level of risk was high because the patient has severe rheumatoid arthritis.
  2. C: 96413: The infliximab infusion was 35 minutes along before it was stopped because of an adverse reaction. The first hour of an infusion must be at least 16 minutes long in order to qualify as an infusion. If the first hour is less than 16 minutes, it must be coded as a chemotherapy push—96401. Descriptions of each code are below:
    • 96413—Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug
    • 96401—Chemotherapy administration, subcutaneous or intramuscular, nonhormonal antineoplastic
  3. C: 96375: The push would be coded as a subsequent push because only one initial code in the drug administration family—96413—can be billed during a session.
    • 96375—each additional sequential intravenous push of a new substance/drug (list separately in addition to code for primary procedure)
  4. D: 96361-59: As stated in answer three above, only one initial code is allowed per session. The infusion of hydration is only allowed if the saline is used to remove the drug from a patient in the case of an adverse reaction. The modifier -59 is required to get this charge reimbursed.
  5. C: 20: The code for the infliximab is 20—J1745 10 mg. To arrive at the number of units to be billed, divide 200 mg—the amount of the drug used—by 10.
    • J1745–Injection, infliximab, 10 mg

Filed Under: Billing/Coding, Conditions, Practice Management, Rheumatoid Arthritis Tagged With: Billing, Coding, drug, infliximab, Practice Management, Rheumatoid arthritis, rheumatologistIssue: December 2012

You Might Also Like:
  • Coding Corner Answer: July Coding Challenge
  • Coding Corner Answer: August Coding Challenge
  • Coding Corner Question: December
  • Coding Corner Answer: September

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)